Genelux (GNLX) Assets Average (2023 - 2026)

Genelux (GNLX) posted quarterly Assets Average of $25.7 million for Q1 2026, up 16.78% quarter-over-quarter from $22.0 million in Q4 2025.

Genelux (GNLX) Assets Average (2023 - 2026) Analysis & Trends

Genelux's Assets Average history runs 4 years deep, the most recent figure standing at $25.7 million for Q1 2026.

In Q1 2026, Assets Average changed N/A year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at $25.7 million (changed N/A YoY), while the FY2025 annual figure was $26.9 million, down 14.16% from the prior year.
Assets Average for Q1 2026 stood at $25.7 million, up from $22.0 million in the prior quarter.
The five-year high for Assets Average was $42.7 million in Q3 2024, with the low at $22.0 million in Q4 2025.
The 4-year median for Assets Average is $29.8 million (2023), against an average of $31.1 million.
The sharpest annual moves came in 2024 and 2025: Assets Average gained 21.01% in 2024, then tumbled 41.3% in 2025.
Genelux's Assets Average stood at $31.0 million in 2023, then climbed by 21.01% to $37.5 million in 2024, then sank by 41.3% to $22.0 million in 2025, then grew by 16.78% to $25.7 million in 2026.
Business Quant data shows GNLX's Assets Average at $25.7 million in Q1 2026, $22.0 million in Q4 2025, and $28.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	26.95 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	41.30 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	11.22 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	8.86 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	5.34 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	25.27 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	2.09 Bn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.82 Bn
10	Genelux	119.87 Mn	119.87 Mn	-	25.70 Mn

Download Data